T-1101 granted the MOEA 2011 Breakthrough Innovation of the Year Award
2011.11.09
Taivex corporate with Development Center for Biotechnology (DCB), developed a first-in-class small molecule drug, T-1101. T-1101 is novel oral powder dosage Hec1/Nek2 inhibitor, which block